Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | MAX | P61244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340531 | 0.89 | AURKA (0.40) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL6701777 | 0.89 | AURKA (0.39) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL6695295 | 0.89 | AURKA (0.40) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL1343244 | 0.89 | AURKA (0.40) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL1343247 | 0.88 | ITGB1 (0.37) | MAPK14MAPK13LPAR1MYCMAX | |
| SCHEMBL6695225 | 0.87 | AURKA (0.39) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL1342817 | 0.87 | ADRB2 (0.40) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL1342497 | 0.85 | ITGB1 (0.42) | MAPK14MAPK13LPAR1MYCMAX | |
| SCHEMBL1342216 | 0.84 | AURKA (0.39) | AURKAAURKBMAPK14MAPK13LPAR1 | |
| SCHEMBL1342997 | 0.84 | NAMPT (0.40) | MAPK14LPAR1MYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | AURKA 3432/4885AURKB 2691/4885MAPK14 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.